-15-01

Express Mail Label No.: EL862266190US Date of Deposit: October 12, 2001

Re ceipt
Attorney Docket No. 22058 521
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

APPLICANTS: Keith et al.

09/521,696 SERIAL NUMBER:

EXAMINER: Not Yet Assigned

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED

CYTOTOXICITY

Application Processing Division's **Customer Correction Branch**

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

Request for corrected filing receipt (1 page);

Copy of filing receipt marked with correction (3 pages); and

Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 22058-521. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully subthitted

Ivor R. Elrifi, Reg. No. 39,529

David E. Johnson, Reg. No. 41,81/4

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 press Mail Label No.: EL862266190US

f Deposit: October 12, 2001

Attorney Docket No.: 22058-521

RECEIVED

NOV 0 2 2001 TECH CENTER 1600/2900

CANTS:

Keith et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NUMBER:

09/521.696

EXAMINER:

Not Yet Assigned

FILING DATE:

March 9, 2000

ART UNIT:

FOR:

USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED

CYTOTOXICITY

Office of Initial Patent Examiner's

Customer Service Center

Assistant Commissioner for Patents

Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

- Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants enclose a copy of the Filing Receipt with the corrections noted thereon. Issuance of a corrected filing receipt is respectfully requested.
- There are errors with respect to the following data, which are incorrectly entered.

Error in

Correct data

Attorney Name

Ivor R. Elrifi, Ph.D.

Attorney Address

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center Boston, MA 02111

Attorney Docket No.

22058-521

The correction is not due to any error by Applicants and Applicants believe that no fee is due. However, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 220 8-521.

Dated: October 12, 2001

Respectfully sub

Ivor R. Elrifi, Reg. No. 39,529 David E. Johnson, Reg. No. 41/874

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

P.02/03 د دن د علام



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE TCH. D.C. 20231

APPLICATION NUMBER 09/521,696

FILING DATE

GRP ART UNIT

FIL FEE REC'D ATTY. DOCKET. NO

DRAWINGS TOT CLAIMS

ww.uspto.gov IND CLAMS

03/09/2000

1647

820

GI-5345-

3

22058-521

CONFIRMATION NO. 2455

CORRECTED FILING RECEIPT RAY E. BRADY AMERICAN HOME PRODUCTS CORPORATION

PATENT DEPARTMENT- 2B ONE CAMPUS DRIVE

PARSIPPANY, NJ 07054

AUG 2 4 2001

22078-521

IVOR R. ELRIFI, PH.D.

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

MINTZ LEVIN, BOSTON PATENT DOCKET DEPT.

Date Mailed: 07/31/2001

Done By

ONE FINANCIAL CENTER, BOSTON, 02111

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James Keith, Andover, MA; Joseph M. Carroll, Manchester, MA; Jordan S. Pober, Guilford, CT.

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/124,024 03/11/1999

Foreign Applications

If Required, Foreign Filing License Granted 05/18/2000

CPA filed on: 05/10/2001

Projected Publication Date: 11/08/2001

Non-Publication Request: No

Early Publication Request: No

RECEIVED

□ Data Entry ☐ Docket Entry

☐ ELITE ☐ Annuities

☐ Docket Cross Of

Previously Entered ☐ No Docketing Req

AUG 02 2001

CONTROL CROMER


Title

Use of interleukin-11 to prevent immune-mediated cytotoxicity



NOV 0 2 200

TECH CENTER 1600/2900



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
37, Cod of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 6.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form, Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 36 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application.
 They are considered to be unnecessary to the understanding of the title.
- The words "new," "Improved," "improvements In" or "relating to" are not included as first words in th
 title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on th Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231